AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11050518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (droperidol + ondansetron)
Number of subjects: 90
Study 10170301 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0
Study 10170301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8289409 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-derived long-chain triglycerides (LCTs) emulsion
Number of subjects: 7
Study 8289409 — intervention group
Group type: EXPERIMENTAL
Intervention: Long- and medium-chain triglycerides (MCTs/LCTs) emulsion
Number of subjects: 7
Study 3755581 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha, 25‐dihydroxycholecalciferol (Rocaltrol)
Number of subjects: 0
Study 3755581 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha‐hydroxycholecalciferol (One‐Alpha)
Number of subjects: 0
Study 3755581 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28807536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lockable household pesticide storage containers distributed to intervention households (20,457 containers).
Number of subjects: 223861
Study 28807536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lockable household pesticide storage containers (intervention).
Number of subjects: 223861
Study 28807536 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control).
Number of subjects: 223861
Study 26365210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifitegrast ophthalmic solution 5.0%, twice daily for 84 days
Number of subjects: 718
Study 26365210 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 84 days
Number of subjects: 718
Study 26365210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifitegrast ophthalmic solution 5.0%
Number of subjects: 718
Study 26365210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718
Study 23334069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponezumab 1 mg/kg
Number of subjects: 15
Study 23334069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponezumab 3 mg/kg
Number of subjects: 15
Study 23334069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponezumab 5 mg/kg
Number of subjects: 15
Study 23334069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponezumab 10 mg/kg
Number of subjects: 15
Study 23334069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponezumab (all doses)
Number of subjects: 15
Study 21062338 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching platform implants
Number of subjects: 14
Study 21062338 — intervention group
Group type: COMPARATOR
Intervention: Traditional platform implants (control group)
Number of subjects: 14
Study 19207079 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial low-dose gentamicin with standard therapy (antistaphylococcal penicillin or vancomycin)
Number of subjects: 236
Study 19207079 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial low-dose gentamicin
Number of subjects: 236
Study 19207079 — intervention group
Group type: COMPARATOR
Intervention: Daptomycin monotherapy
Number of subjects: 236
Study 19207079 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 236
Study 19207079 — intervention group
Group type: COMPARATOR
Intervention: Antistaphylococcal penicillin
Number of subjects: 236
Study 17213274 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 3548
Study 17213274 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle, metformin, or troglitazone
Number of subjects: 3548
Study 17213274 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARG P12A genotype
Number of subjects: 3548
Study 17213274 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index and waist circumference
Number of subjects: 3548
Study 15823765 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg
Number of subjects: 36
Study 15823765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 36
Study 15823765 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet (Oxycodone 5 mg + Ibuprofen 400 mg)
Number of subjects: 36
Study 11565840 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-β3 (25 μg/mL) applied as mouthwash four times daily
Number of subjects: 152
Study 11565840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 9692458 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated bypass circuits
Number of subjects: 19
Study 9692458 — intervention group
Group type: COMPARATOR
Intervention: Noncoated bypass circuits (Control)
Number of subjects: 19
Study 7931456 — intervention group
Group type: EXPERIMENTAL
Intervention: VISI-CAARE
Number of subjects: 20
Study 7931456 — intervention group
Group type: COMPARATOR
Intervention: Traditional pen and paper
Number of subjects: 20
Study 7931456 — intervention group
Group type: EXPERIMENTAL
Intervention: VISI-CAARE 1.1
Number of subjects: 20
Study 2972167 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (200 mg 3 times daily)
Number of subjects: 59
Study 2972167 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Medroxyprogesterone Acetate (MPA, 100 mg daily)
Number of subjects: 59
Study 2972167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 31661809 — intervention group
Group type: EXPERIMENTAL
Intervention: Detoxification intervention (exercise, sauna-induced sweating, crystalline nicotinic acid, and other supplements)
Number of subjects: 32
Study 31661809 — intervention group
Group type: EXPERIMENTAL
Intervention: Detoxification intervention
Number of subjects: 32
Study 31661809 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 32
Study 28434014 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg on the first day, followed by 100 mg once daily for 12 weeks)
Number of subjects: 60
Study 28434014 — intervention group
Group type: COMPARATOR
Intervention: Nasal steroids and saline irrigation (control group)
Number of subjects: 60
Study 25955397 — intervention group
Group type: EXPERIMENTAL
Intervention: NCP (80-kV and dual-phase scanning)
Number of subjects: 60
Study 25955397 — intervention group
Group type: COMPARATOR
Intervention: RCP (120-kV and single-phase scanning)
Number of subjects: 60
Study 24047312 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of renal function
Number of subjects: 35502
Study 24047312 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR < 60 ml/min, proteinuria, and hypertension
Number of subjects: 35502
Study 21411556 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial skin color change (measured by ITA)
Number of subjects: 314
Study 21411556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen use
Number of subjects: 314
Study 21411556 — intervention group
Group type: COMPARATOR
Intervention: Body mass index quartile comparison
Number of subjects: 314
Study 19491183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral (CB) prevention program consisting of 8 weekly, 90-minute group sessions followed by 6 monthly continuation sessions
Number of subjects: 316
Study 19491183 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 316
Study 19491183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral (CB) prevention program
Number of subjects: 316
Study 17944741 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed of their negative H. pylori status
Number of subjects: 2708
Study 17944741 — intervention group
Group type: COMPARATOR
Intervention: Placebo triple therapy
Number of subjects: 2708
Study 15789980 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate 360 degrees toothbrush
Number of subjects: 82
Study 15789980 — intervention group
Group type: COMPARATOR
Intervention: Oral-B Indicator toothbrush
Number of subjects: 82
Study 11678487 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dietary counseling to increase vegetable and fruit intake
Number of subjects: 53
Study 11678487 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 53
Study 9854116 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg vesnarinone
Number of subjects: 3833
Study 9854116 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg vesnarinone
Number of subjects: 3833
Study 9854116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3833
Study 8209298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic duct cholangiography (n = 38)
Number of subjects: 69
Study 8209298 — intervention group
Group type: COMPARATOR
Intervention: Cholecystocholangiography (n = 31)
Number of subjects: 69
Study 2589534 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg im atropine (ATR)
Number of subjects: 4
Study 2589534 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 4
Study 30794228 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized zirconium (OxZr) TKA
Number of subjects: 99
Study 30794228 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chrome (CoCr) TKA
Number of subjects: 99
Study 29793677 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of umbilical cord blood platelet gel (CBPG), applied twice a week for 4 weeks and then once a week for an additional 4 weeks.
Number of subjects: 20
Study 29793677 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care (control group).
Number of subjects: 20
Study 25986314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrotuss(®)
Number of subjects: 20
Study 25986314 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox(®)
Number of subjects: 20
Study 25986314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22789423 — intervention group
Group type: EXPERIMENTAL
Intervention: Condylectomy with osteoarthrectomy and interposition with a temporalis muscle flap
Number of subjects: 22
Study 22789423 — intervention group
Group type: COMPARATOR
Intervention: Condylectomy and osteoarthrectomy alone
Number of subjects: 22
Study 21701239 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intervention
Number of subjects: 188
Study 21701239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 188
Study 21701239 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 188
Study 19170852 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 4174
Study 19170852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4174
Study 16553702 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated education programme
Number of subjects: 76
Study 14744169 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 157
Study 14744169 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 157
Study 14744169 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 157
Study 14744169 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 157
Study 11410074 — intervention group
Group type: EXPERIMENTAL
Intervention: Petadolex (Petasites hybridus extract), 25 mg per capsule, 2 capsules twice daily for 12 weeks
Number of subjects: 60
Study 11410074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9274634 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical sunscreen
Number of subjects: 25
Study 9274634 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical sunscreen
Number of subjects: 25
Study 9274634 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical sunscreen with varying SPF
Number of subjects: 25
Study 9274634 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with lower skin types
Number of subjects: 25
Study 1927240 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with placebo
Number of subjects: 91
Study 1927240 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with 0.1 mg fentanyl
Number of subjects: 91
Study 1927240 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with placebo
Number of subjects: 91
Study 1927240 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 0.1 mg fentanyl
Number of subjects: 91
Study 6749447 — intervention group
Group type: EXPERIMENTAL
Intervention: ribavirin
Number of subjects: 60
Study 6749447 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 30426256 — intervention group
Group type: COMPARATOR
Intervention: TR-RALP (traditional robot-assisted laparoscopic radical prostatectomy)
Number of subjects: 102
Study 30426256 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-RALP (Retzius-sparing robot-assisted laparoscopic prostatectomy)
Number of subjects: 102
Study 27939237 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month intervention including a 1-credit college course on healthy weight behaviors and a social networking website for support.
Number of subjects: 441
Study 27939237 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 441
Study 27939237 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month intervention (details as above).
Number of subjects: 441
Study 26732420 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting, platinum-chromium PROMUS Element Plus stents
Number of subjects: 2683
Study 26732420 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PE-Plus population
Number of subjects: 2683
Study 26732420 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting, platinum-chromium PROMUS Element Plus stents in diabetic patients
Number of subjects: 2683
Study 23405070 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat/high energy shake
Number of subjects: 20
Study 23405070 — intervention group
Group type: COMPARATOR
Intervention: Average breakfast shake
Number of subjects: 20
Study 21057736 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management intervention (weeks 1-16)
Number of subjects: 102
Study 21057736 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (weeks 17-32)
Number of subjects: 102
Study 19054193 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan training for 1 hour twice a week for 13 weeks
Number of subjects: 269
Study 19054193 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 269
Study 19054193 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan training
Number of subjects: 269
Study 16907703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ser49Gly polymorphism of the beta1 ADR in hypertensive African-Americans
Number of subjects: 0
Study 16907703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ser49Gly polymorphism of the beta1 ADR in hypertensive whites
Number of subjects: 0
Study 16907703 — intervention group
Group type: EXPERIMENTAL
Intervention: Arg389Gly polymorphism of the beta1 ADR in normotensive African-Americans
Number of subjects: 0
Study 16907703 — intervention group
Group type: EXPERIMENTAL
Intervention: beta1 haplotype (Ser49Gly-Arg389Gly) in hypertensive African-Americans
Number of subjects: 0
Study 16907703 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha2B C/A polymorphism in hypertensive whites
Number of subjects: 0
Study 16907703 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha2B C/A polymorphism in both whites and African-Americans taking beta-blockers
Number of subjects: 0
Study 15036054 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefrontal TMS at 4 different stimulus intensities (60, 80, 100, and 120% of MT)
Number of subjects: 9
Study 15036054 — intervention group
Group type: COMPARATOR
Intervention: Motor cortex TMS
Number of subjects: 9
Study 11711728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg daily
Number of subjects: 26
Study 11711728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9654800 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based alcohol and drug abuse prevention program
Number of subjects: 324
Study 9654800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 324
Study 7995324 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin (300 mg)
Number of subjects: 10
Study 7995324 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 3046299 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin E supplementation at doses up to 3200 mg/d (3200 IU/d)
Number of subjects: 0
Study 3046299 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin E supplementation
Number of subjects: 0
Study 3046299 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal studies of vitamin E
Number of subjects: 0
Study 29651816 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly theoretical and hands-on guidance from dental hygienists on oral hygiene procedures and discussions on oral care routines
Number of subjects: 0
Study 29651816 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 25860384 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled local skin cooling (cryolysis)
Number of subjects: 0
Study 24178765 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (vodka 37.5% at a dose of 46.5 g ethanol)
Number of subjects: 52
Study 24178765 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol in combination with caffeine at a dose of 80 mg
Number of subjects: 52
Study 24178765 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol in combination with energy drink at a dose of 250 ml
Number of subjects: 52
Study 24178765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21175704 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic omeprazole 20 mg once daily
Number of subjects: 24
Study 21175704 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily
Number of subjects: 24
Study 18511540 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical travoprost 0.004% once daily for 6 months
Number of subjects: 88
Study 18511540 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 88
Study 16970646 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-morning nutritional supplement for 3 weeks
Number of subjects: 30
Study 14556728 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) 0.05-0.1 mg/kg per day
Number of subjects: 125
Study 14556728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 10890288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 397
Study 10890288 — intervention group
Group type: COMPARATOR
Intervention: Twelve-Step Facilitation therapy (TSF)
Number of subjects: 397
Study 9562649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (mean dose 240 mg q.d., max. 320 mg)
Number of subjects: 17
Study 9562649 — intervention group
Group type: COMPARATOR
Intervention: Control group (without sotalol)
Number of subjects: 17
Study 9562649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 17
Study 7687736 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart audit with feedback
Number of subjects: 0
Study 7687736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 0
Study 3571753 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (20 micrograms; mean 0.3 micrograms/kg)
Number of subjects: 39
Study 30012607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol intake
Number of subjects: 49
Study 30012607 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (TSD; 35 hours awake)
Number of subjects: 49
Study 30012607 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (PSD; four nights with 5 hours scheduled sleep)
Number of subjects: 49
Study 30012607 — intervention group
Group type: COMPARATOR
Intervention: Ethanol infusion
Number of subjects: 49
Study 26708330 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal disordered eating prevention program
Number of subjects: 152
Study 26708330 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 413 girls) from eleven schools in four neighboring towns
Number of subjects: 152
Study 24374115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 45 min, three intravenous infusions)
Number of subjects: 18
Study 24374115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 45 min, second dose)
Number of subjects: 18
Study 24374115 — intervention group
Group type: COMPARATOR
Intervention: ECT (electroconvulsive therapy, administered on 3 test days every 48 hours)
Number of subjects: 18
Study 24011296 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite post restorations
Number of subjects: 54
Study 24011296 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber post restorations
Number of subjects: 54
Study 24011296 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed post restorations
Number of subjects: 54
Study 21365332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillations with 40 ml chondroitin sulfate 0.2% solution
Number of subjects: 20
Study 21365332 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instillations)
Number of subjects: 20
Study 18959492 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug conservation (interrupt antiretroviral therapy until CD4(+) cell count <250 cells/microL)
Number of subjects: 5472
Study 18959492 — intervention group
Group type: COMPARATOR
Intervention: Viral suppression (continued use of antiretroviral therapy)
Number of subjects: 5472
Study 17161785 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein ablation
Number of subjects: 100
Study 17161785 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental pulmonary vein ablation
Number of subjects: 100
Study 14567368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox gel 0.77% applied twice daily for 28 days
Number of subjects: 374
Study 14567368 — intervention group
Group type: COMPARATOR
Intervention: Ciclopirox gel vehicle applied twice daily for 28 days
Number of subjects: 374
Study 10912845 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) measurements using the Osteometer DTU-one (imaging) device
Number of subjects: 423